NCT01726790

Effect of Intravitreal Bevacizumab on Corneal Endothelium

• Status: Unknown
• Phase: —
• Study type: Observational
• Enrollment: 37 (estimated)
• Sponsor: Khon Kaen University · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

To evaluate corneal endothelium cell change after intravitreal Bevacizumab injection

Detailed description

Intravitreal Bevacizumab has been used by retinal specialist in treatment many retinal diseases. Although it not approved by FDA for treatment. In many In vitro studies, its showed saftey in the eyes especially for corneal endothelium cells, that important cells to keep cornea clear. This study use Confoscan-Corneal confocal microsope to evaluate corneal endothelium before and after intravitreal Bevacizumab injection in routine retinal disease at 6 month follow up.

Conditions

• Corneal Endothelial Cell Loss

Timeline

• Start date: 2011-08-01
• Primary completion: 2013-06-01
• Completion: 2013-10-01
• First posted: 2012-11-15
• Last updated: 2012-11-15

Locations

1 site across 1 country: Thailand